Navigation Links
Differing Ideas on Management of Alzheimer’s diseas

Doctors allege that memory clinics and drugs to retard the progress of symptoms of Alzheimer's disease are diverting resources from high quality integrated care in state-funded health services.//

The National Institute for Health and Clinical Excellence (NICE) had recommended treatments known as cholinesterase inhibitors for patients with mild-to-moderate Alzheimer's disease since 2001.

However psychiatrist Anthony Pelosi of the Hairmyres Hospital in East Kilbride, Scotland and his colleagues said that memory clinics that were initially set up to prescribe and monitor the medicines have distorted clinical priorities.

Pelosi said, "These clinics are diverting resources from high quality integrated care." He added that these drugs, which cost about 1,000 pounds per patient per year, have been found to be of marginal benefit from statistical, clinical and public health perspectives.

According to Pelosi and his colleagues although memory clinics recruited multidisciplinary staff, there is a shortage of mental health professionals in Britain. In addition the clinics do not offer care in the community for their patients as their illness progresses.

The 2001 decision by NICE stressed that further research would be needed and that the recommendation would be reviewed in several years.

In March 2005, NICE recommended these drugs must be stopped from being given to new patients because they were not cost effective. The Royal College of Psychiatrists and the Association of the British Pharmaceutical Industry condemned the decision, which NICE said was provisional and subject to consultations.

It has been estimated that 12 million people worldwide suffer from Alzheimer's which is the leading cause of dementia in the elderly.

Novartis AG's Exelon; Pfizer Inc and Eisai Co's Aricept; and Reminyl, made by Johnson & Johnson and distributed in Britain by Shire Pharmaceuticals Group are leading cholinesterase in hibitors.

Pelosi added, "Whatever the final outcome of NICE's deliberations, the human and financial resources that have become tied up in clinics organised around prescription of cholinesterase inhibitors must be diverted to old age psychiatry teams and their social care counterparts."


NLA
'"/>




Related medicine news :

1. Differing reactions to anti clotting drugs may be due to genetic variation.
2. New Ideas on Developing Thought-Controlled Artificial Limbs
3. New Modality in Migraine Management
4. Self-Management Program Beneficial for Back Pain
5. Self-Management Program Beneficial for Back Pain
6. Disease Management Programs – Effective for Heart Patient
7. Effective Management Of Heart Patients
8. Gastrin, Much More Than The Weight Management Hormone
9. Medical Management Now Available For Miscarriage
10. Early Awareness About Weight Management Needed To Tackle Lifelong Obesity
11. Exercise For Effective Pain Management In Old People
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/9/2016)... ... ... Establishment Labs, a global breast implant and medical technology company, is pleased ... , “We are honored to welcome David to our Board of Directors. ... Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable to our ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... service to expand access to affordable hearing aids , increase industry transparency, ... individuals in the United States. , “For the average consumer, the hearing aid ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... sealing company , is proud to announce that many of their franchises have ... customer service. The hard surface restoration franchises received customer recognition through positive reviews ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal Laboratory ... federallabs.org . The site houses a wealth of federal resources that businesses can ... process called technology transfer (T2). As a network of over 300 federal laboratories, ...
(Date:2/8/2016)... Los Angeles, CA (PRWEB) , ... February 08, 2016 , ... A man who has ... CEO of Freedom Laser Therapy , was determined to find solutions to his problems ... story of Inventors Digest is ready to introduce his breakthrough inventions to the ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... , February 9, 2016 ... QIA) gab heute den Abschluss eines Kooperationsvertrags ... Förderung umfassender Lösungen in den Bereichen Next-Generation-Sequencing ... QGEN ; Frankfurt Prime Standard: QIA) ... 10x Genomics für die Entwicklung und Förderung ...
(Date:2/9/2016)... 9, 2016 Mast Therapeutics, Inc. (NYSE ... sickle cell disease and heart failure, today announced that it ... purchase common stock in an underwritten public offering.  The offering ... be no assurance as to whether or when the offering ... terms of the offering.   --> ...
(Date:2/9/2016)... 9, 2016 Hearing protection devices refer to ... transmitted to the inner ear. Hearing protection devices include ... devices are recommended for users exposed to noise levels ... to HPD that are inserted in the ear canal ... to provide more natural sound perception with the help ...
Breaking Medicine Technology: